Correlation Between Protalix Biotherapeutics and Checkpoint Therapeutics
Can any of the company-specific risk be diversified away by investing in both Protalix Biotherapeutics and Checkpoint Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protalix Biotherapeutics and Checkpoint Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protalix Biotherapeutics and Checkpoint Therapeutics, you can compare the effects of market volatilities on Protalix Biotherapeutics and Checkpoint Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protalix Biotherapeutics with a short position of Checkpoint Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protalix Biotherapeutics and Checkpoint Therapeutics.
Diversification Opportunities for Protalix Biotherapeutics and Checkpoint Therapeutics
0.7 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Protalix and Checkpoint is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Protalix Biotherapeutics and Checkpoint Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Checkpoint Therapeutics and Protalix Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protalix Biotherapeutics are associated (or correlated) with Checkpoint Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Checkpoint Therapeutics has no effect on the direction of Protalix Biotherapeutics i.e., Protalix Biotherapeutics and Checkpoint Therapeutics go up and down completely randomly.
Pair Corralation between Protalix Biotherapeutics and Checkpoint Therapeutics
Considering the 90-day investment horizon Protalix Biotherapeutics is expected to generate 1.28 times less return on investment than Checkpoint Therapeutics. But when comparing it to its historical volatility, Protalix Biotherapeutics is 1.39 times less risky than Checkpoint Therapeutics. It trades about 0.04 of its potential returns per unit of risk. Checkpoint Therapeutics is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest 372.00 in Checkpoint Therapeutics on August 30, 2024 and sell it today you would earn a total of 56.00 from holding Checkpoint Therapeutics or generate 15.05% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Protalix Biotherapeutics vs. Checkpoint Therapeutics
Performance |
| Timeline |
| Protalix Biotherapeutics |
| Checkpoint Therapeutics |
Protalix Biotherapeutics and Checkpoint Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Protalix Biotherapeutics and Checkpoint Therapeutics
The main advantage of trading using opposite Protalix Biotherapeutics and Checkpoint Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protalix Biotherapeutics position performs unexpectedly, Checkpoint Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Checkpoint Therapeutics will offset losses from the drop in Checkpoint Therapeutics' long position.| Protalix Biotherapeutics vs. Corvus Pharmaceuticals | Protalix Biotherapeutics vs. Aldeyra | Protalix Biotherapeutics vs. Checkpoint Therapeutics | Protalix Biotherapeutics vs. Cidara Therapeutics |
| Checkpoint Therapeutics vs. Mustang Bio | Checkpoint Therapeutics vs. Reviva Pharmaceuticals Holdings | Checkpoint Therapeutics vs. Fortress Biotech Pref | Checkpoint Therapeutics vs. Kodiak Sciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |